Company Analysis

Amylyx Pharmaceuticals, Inc. (AMLX)

Nasdaq: AMLX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2015
Grade5.4
◀ Past 5.1● Present 6.3▶ Future 4.8
5 est.

Who runs Amylyx Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Cohen Joshua B
Co-Chief Executive Officer. First filing Jan 2022, latest Nov 12, 2026, 16 filings in all.
Officers reporting now
5
of 10 people with a filing in the last fifteen months
Directors reporting now
5
13 people on the record since 2022
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Cohen Joshua BCo-Chief Executive OfficerJan 2022Nov 12, 20269 · $6.6M
Klee Justin B.Co-Chief Executive OfficerJan 2022Nov 12, 20269 · $6.6M
Frates James MChief Financial OfficerJan 2022Nov 12, 20269 · $1.8M
Bedrosian Camille LChief Medical OfficerNov 2023Sep 14, 20264 · $500,000
Mazzariello GinaChief Legal OfficerFeb 2022Sep 14, 20267 · $1.0M
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Milne George M JrdirectorJan 2022Oct 7, 20261 · $800,000
Firestone KarendirectorMar 2023Sep 2, 2026none
Fonteyne Paul R.directorJan 2022Jun 8, 2026none
Quimi DaphnedirectorJan 2022Jun 8, 2026none
Zeiher Bernhardt GdirectorMar 2024Jun 8, 2026none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton AMLX · research, not advice